We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Vertex Pharmaceuticals Inc | NASDAQ:VRTX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 2.74 | 0.56% | 495.00 | 490.01 | 502.00 | 502.97 | 492.165 | 493.70 | 775,803 | 01:00:00 |
From Jul 2023 to Jul 2024
By Denny Jacob
Vertex Pharmaceuticals' has gained market authorization from Health Canada for the expanded use of Kalydeco to treat cystic fibrosis in certain children aged two months and up.
The biotechnology company said the latest authorization of Kalydeco is for children with certain mutations in the cystic fibrosis transmembrane conductance regulator gene.
Vertex said it will work closely with government and private payers to facilitate access for eligible patients as soon as possible.
Kalydeco was previously approved by Health Canada for use in people with cystic fibrosis aged four months and older with certain gene mutations.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
November 29, 2023 14:40 ET (19:40 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Vertex Pharmaceuticals Chart |
1 Month Vertex Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
